Literature DB >> 10711854

Pharmacological factors that influence the choice of inhaled corticosteroids.

S Edsbäcker1.   

Abstract

Local therapeutic effect relative to the risk of adverse effects of inhaled drugs, i.e. airway selectivity, is determined by the efficiency of the delivery system and the physicochemical and pharmacokinetic properties of the drug molecule. For the inhaled corticosteroid formulations, many of the pharmacokinetic prerequisites for airway selectivity have been fulfilled, but there are still differences that may influence the choice of treatment regimens. This choice should be based on disease severity, age, inhalation technique, preference and expected compliance, together with a knowledge of individual features of different corticosteroid formulations. Simple to use, hand-held pressurised or breath-actuated inhalers have favourable lung deposition properties and are appropriate for most patients. For small children or severely ill patients, nebulised treatment or spacers may be advocated. A corticosteroid formulation with a high intrinsic activity and long duration of action allows for once-daily administration in some patient groups. These properties may also partly compensate for noncompliance when more frequent administration schemes are used. The risk of adverse effects is reduced if systemic exposure is held to a minimum by rapid elimination and low tissue distribution.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10711854     DOI: 10.2165/00003495-199958004-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  33 in total

Review 1.  Anti-inflammatory actions of steroids: molecular mechanisms.

Authors:  P J Barnes; I Adcock
Journal:  Trends Pharmacol Sci       Date:  1993-12       Impact factor: 14.819

Review 2.  Efficacy and safety of inhaled corticosteroids. New developments.

Authors:  P J Barnes; S Pedersen; W W Busse
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

3.  Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model.

Authors:  G Hochhaus; H Möllmann; H Derendorf; R J Gonzalez-Rothi
Journal:  J Clin Pharmacol       Date:  1997-10       Impact factor: 3.126

4.  Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects.

Authors:  L Thorsson; K Dahlström; S Edsbäcker; A Källén; J Paulson; J E Wirén
Journal:  Br J Clin Pharmacol       Date:  1997-02       Impact factor: 4.335

5.  Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo.

Authors:  N Esmailpour; P Högger; K F Rabe; U Heitmann; M Nakashima; P Rohdewald
Journal:  Eur Respir J       Date:  1997-07       Impact factor: 16.671

6.  Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line In vitro.

Authors:  E Wieslander; E L Delander; L Järkelid; E Hjertberg; A Tunek; R Brattsand
Journal:  Am J Respir Cell Mol Biol       Date:  1998-09       Impact factor: 6.914

7.  Inhibition of antigen-induced airway hyperresponsiveness by ultralow molecular-weight heparin.

Authors:  J F Molinari; C Campo; S Shakir; T Ahmed
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

8.  Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes.

Authors:  A Tunek; K Sjödin; G Hallström
Journal:  Drug Metab Dispos       Date:  1997-11       Impact factor: 3.922

9.  CYP3A gene expression in human gut epithelium.

Authors:  J C Kolars; K S Lown; P Schmiedlin-Ren; M Ghosh; C Fang; S A Wrighton; R M Merion; P B Watkins
Journal:  Pharmacogenetics       Date:  1994-10

10.  A double-blind comparison between a new multidose powder inhaler (Turbuhaler) and metered dose inhaler in children with asthma.

Authors:  C Hultquist; H Ahlström; N I Kjellman; L A Malmqvist; E Svenonius; S Melin
Journal:  Allergy       Date:  1989-09       Impact factor: 13.146

View more
  9 in total

Review 1.  Rationale for once-daily therapy in asthma: compliance issues.

Authors:  M E Hyland
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.

Authors:  L Thorsson; S Edsbäcker; A Källén; C G Löfdahl
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

3.  Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo.

Authors:  H Petersen; A Kullberg; S Edsbäcker; L Greiff
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 4.  Inhaled budesonide/formoterol combination.

Authors:  J K McGavin; K L Goa; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders.

Authors:  K M Hvizdos; B Jarvis
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

6.  Evidence of the in vivo esterification of budesonide in human airways.

Authors:  Karen I Maassen van den Brink; Martin Boorsma; A Jeske Staal-van den Brekel; Staffam Edsbäcker; Emiel F Wouters; Lars Thorsson
Journal:  Br J Clin Pharmacol       Date:  2008-04-01       Impact factor: 4.335

Review 7.  Budesonide/formoterol: a review of its use in asthma.

Authors:  David R Goldsmith; Gillian M Keating
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Budesonide/formoterol: in chronic obstructive pulmonary disease.

Authors:  Neil A Reynolds; Caroline M Perry; Gillian M Keating
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Budesonide-formoterol (inhalation powder) in the treatment of COPD.

Authors:  Erkan Ceylan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.